Skip to content
soligenix-logo Soligenix
Main Menu
  • About
    • Corporate Overview
    • Board of Directors
    • Executive Team
    • Scientific Advisory Boards
      • Cutaneous T-Cell Lumphoma
      • Oral Mucositis
      • Pediatric Crohn’s Disease
      • Radiation Enteritis
      • Acute Radiation Syndrome
    • Careers
      • Working at Soligenix
      • Job Openings
  • Contact
  • Careers
  • Pipeline + Programs
    • Pipeline
    • Specialized BioTherapeutics
      • SGX301 for Cutaneous T-Cell Lymphoma (CTCL)
      • SGX942 for Oral Mucositis
      • SGX203 for Pediatric Crohn’s Disease
      • SGX201 for Radiation Enteritis
    • Public Health Solutions
      • RiVax® to Prevent Ricin Poisoning
      • SGX943 for Infectious Disease
      • ThermoVax®: Thermostabilized Vaccines for Global Use
    • Reference Literature
      • Specialized BioTherapeutics
      • Public Health Solutions
    • Relevant Publications
  • Clinical Trials
  • Our Focus
    • Specialized BioTherapeutics
      • Cutaneous T-Cell Lymphoma
      • Pediatric Crohn’s Disease
      • Oral Mucositis
      • Radiation Enteritis
    • Public Health Solutions
      • Thermal Stabilization of Vaccines
      • Ricin Exposure
      • GI Acute Radiation Syndrome
      • Melioidosis
  • Partnering
  • Investors
    • Investor Overview
    • News Releases
    • SEC Filings
    • Corporate Governance
    • Stock Information
    • Analyst Coverage
    • Investor Alerts

Company Presentations

Advanced Search
 Basic Search
  • Sep 25, 2020
    Corporate Presentation with Audio
  • Sep 25, 2020
    Corporate Presentation
  • Sep 10, 2020
    Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
  • Jun 16, 2020
    Soligenix Presentation at 2020 MedInvest Infectious Disease & Immunology Conference
  • Jul 24, 2020
    Corporate Presentation Webcast
Loading...
© Soligenix, 2020. All Rights Reserved.
  • Legal Notices
  • Site Map
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
  • Instagram